Join the Greater Copenhagen Microbiome Summit for the latest scientific trends and insights within the microbiome field from companies like BioGaia, Chr. Hansen, Ferring and Novozymes as well as academic experts.
The Greater Copenhagen Microbiome Summit offers a digital venue for bringing together microbiome scientists and companies to define the state of microbiome research and opportunities for collaborations in this emerging multidisciplinary field of science. The event will provide unique collaboration and business opportunities with both local and international stakeholders.
• Antimicrobial resistance and the microbiome
• Immune health and the microbiome in the new normal
• Interconnected microbiomes - from oral health to the systemic effects
• Microbiome, animal health and bio agriculture
The Greater Copenhagen Microbiome Summit is initiated by the Greater Copenhagen Microbiome Signature Project and its partners Medicon Valley Alliance, Copenhagen Capacity and Invest in Skåne. The project aims to position Medicon Valley, the life science cluster of the Greater Copenhagen region, as the most competitive and vital life science cluster in northern Europe.
Globally we are living in unprecedented new times where the focus on infections and immune health has never been stronger.
The microbiome and intimate links to the immune system as they both develop from birth and how nutrition
and other factors profoundly affect our immune health throughout life will be discussed.
The human body is home to trillions of microorganisms living in complex microbial communities developing symbiotic interactions with the host. Each body mucosal site harbours its own microbiome with a specific structure and composition. It is increasingly observed that microbiomes from diverse mucosal sites could be interconnected, either by sharing members of the same bacterial family or taxa, or by producing similar metabolites. In turn, probiotics, defined as live microorganisms which when administered in adequate amounts confer a health benefit into the host, could interact with the gut microbiome and have a strong impact on the oral microbiome as well. During this session we will address the role of probiotics in oral health and discuss their potential impact on systemic diseases.
There has been extensive and global research efforts in the past decade engaging in the study of microbial communities and their important relationship with higher organisms and large ecosystems (air, soil and oceans). Studies have revealed that a host’s or an ecosystem’s microbiome plays an essential role in health and disease/imbalance.
In this session we will take a deeper look at how researching the microbiome of living systems can generate new understanding of how microbiomes affect health and performance of especially animals and plants, and how that can lead to new bioindustrial solutions for animal health and bioagriculture.
A growing number of bacteria are becoming resistant to common antibiotics making antimicrobial resistance a global health concern of increasing magnitude. This session will zoom in on the microbiome as a potential tool and target in the effort to address antimicrobial resistance.
Impact of dietary factors and ingested bacteria on gut microbiota and immune functions
Åsa Håkansson, Associate Professor in Food Hygiene, Department of Food Technology, Engineering and Nutrition, Lund University
The role of the early life microbiome in development of asthma and allergy
Jakob Stokholm, MD, Ph.D., COPSAC and University of Copenhagen
What triggers and promotes celiac disease and can we prevent it? Lessons learnt from observational birth cohort studies
Daniel Agardh, Adjunct Professor, Diabetes and Celiac Unit, EXODIAB, Lund University
Discussion & Q&A
The burden of oral diseases and the importance of maintaining a balanced oral microbiome
Svante Twetman, PhD, Department of Odontology, Faculty of Health and Medical Sciences, University of Copenhagen
Limosilactobacillus reuteri as an oral probiotic – translational journey from clinical questions to preclinical development and clinical applications
Jakob Axelsson, Research Manager, BioGaia
The mouth is an integral part of the human body: the oral health-systemic health connection
Wim Teughels, Professor and Vice-head, Periodontology, Department of Oral Health Sciences, KU Leuven, Belgium
Discussion & Q&A
Applied hologenomics - should microbiome treatments be personalised?
Tom Gilbert, Director of the DNRF Center for Evolutionary Hologenomics, University of Copenhagen
How to study Microbiome Assisted Triticum Resilience In X-dimensions?
Lars Hestbjerg Hansen, Head of the Environmental Microbial Genomics group, Department of Plant and Environmental Sciences, University of Copenhagen
Discussion & Q&A
An exclusive interview with Henriette Dræbye Rosenquist, Managing Director and Country Manager, Pfizer France
Identification of anti-virulence compounds against Methicillin-resistant Staphylococcus aureus (MRSA) from host-adapted bacterial pathogens
Lars Jelsbak, Professor MSO, Department of Biotechnology and Biomedicine, DTU Bioengineering
Mining Microbiomes for Antimicrobial Pharmabiotics – Bacteriocins, Phage and their Lysins
Paul Ross, Director of APC Microbiome Institute, University College Cork, Ireland
Bacteriophages for Modulating Human Microbiome: The PhageBiotix™ and SuperBiotix™ Approaches and Their Potential Applications
Dr. Alexander “Sandro” Sulakvelidze, President and CEO of Intralytix
Discussion & Q&A